Maria Luiza C. Lopes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Luiza C. Lopes has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Acco
Department of Pharmacology, Federal University of Paraná, Curitiba, Brazil
1 shared publication - Alexessander Couto Alves
School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK
1 shared publication - Fabiane Gomes de Moraes Rego
Graduate Program in Pharmaceutical Sciences, Federal University of Parana, Curitiba 80210-170, PR, Brazil
1 shared publication - Gabriel Barros Baptistella
SENAI Institute of Innovation in Electrochemistry, 80215-090, Curitiba-PR, Brazil
1 shared publication - Geraldo Picheth
Graduate Program in Pharmaceutical Sciences, Federal University of Parana, Curitiba 80210-170, PR, Brazil
1 shared publication - Giovana Gioppo Nunes
Departamento de Química, Universidade Federal do Paraná, Centro Politécnico, Jardim das Américas, 81530-900 Curitiba-PR, Brazil
1 shared publication
Latest Publications
- Open Access
- 11 April 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (4) , 486
A Non-Toxic Binuclear Vanadium(IV) Complex as Insulin Adjuvant Improves the Glycemic Control in Streptozotocin-Induced Diabetic Rats
Diabetes mellitus (DM) complications are a burden to health care systems due to the associated consequences of poor glycemic control and the side effects of insulin therapy. Recently. adjuvant therapies, such as vanadium compounds, have gained attention due to their potential to improve glucose homeostasis in patients with diabetes. In order to determine the anti-diabetic and antioxidant effects of the oxidovanadium(IV) complex (Et3NH)2[{VO(OH}2)(ox)2(µ–ox)] or Vox2), rats with streptozotocin (STZ)-induced diabetes were treated with 30 and 100 mg/kg of Vox2, orally administered for 12 days. Vox2 at 100 mg/kg in association with insulin caused a 3.4 times decrease in blood glucose in STZ rats (424 mg/dL), reaching concentrations similar to those in the normoglycemic animals (126 mg/dL). Compared to insulin alone, the association with Vox2 caused an additional decrease in blood glucose of 39% and 65% at 30 and 100 mg/kg, respectively, and an increased pancreatic GSH levels 2.5 times. Vox2 alone did not cause gastrointestinal discomfort, diarrhea, and hepatic or renal toxicity and was not associated with changes in blood glucose level, lipid profile, or kidney or liver function. Our results highlight the potential of Vox2 in association with insulin in treating diabetes.
- 11 April 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (4) , 486
Open AccessA Non-Toxic Binuclear Vanadium(IV) Complex as Insulin Adjuvant Improves the Glycemic Control in Streptozotocin-Induced Diabetic Rats
Diabetes mellitus (DM) complications are a burden to health care systems due to the associated consequences of poor glycemic control and the side effects of insulin therapy. Recently. adjuvant therapies, such as vanadium compounds, have gained attention due to their potential to improve glucose homeostasis in patients with diabetes. In order to determine the anti-diabetic and antioxidant effects of the oxidovanadium(IV) complex (Et3NH)2[{VO(OH}2)(ox)2(µ–ox)] or Vox2), rats with streptozotocin (STZ)-induced diabetes were treated with 30 and 100 mg/kg of Vox2, orally administered for 12 days. Vox2 at 100 mg/kg in association with insulin caused a 3.4 times decrease in blood glucose in STZ rats (424 mg/dL), reaching concentrations similar to those in the normoglycemic animals (126 mg/dL). Compared to insulin alone, the association with Vox2 caused an additional decrease in blood glucose of 39% and 65% at 30 and 100 mg/kg, respectively, and an increased pancreatic GSH levels 2.5 times. Vox2 alone did not cause gastrointestinal discomfort, diarrhea, and hepatic or renal toxicity and was not associated with changes in blood glucose level, lipid profile, or kidney or liver function. Our results highlight the potential of Vox2 in association with insulin in treating diabetes.